BioLineRx (BLRX) Profit After Tax (2013 - 2025)

BioLineRx's Profit After Tax history runs 13 years deep, the most recent figure standing at -$2.2 million for Q4 2025.

• In Q4 2025, Profit After Tax rose 29.84% year-over-year to -$2.2 million; the TTM figure through Dec 2025 stood at $5.9 million (up 163.49% YoY), while the FY2025 annual figure was -$2.0 million, up 78.03% from the prior year.
• Profit After Tax was -$2.2 million for Q4 2025 at BioLineRx, down from -$977000.0 in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $18.5 million in Q2 2023 to a low of -$16.0 million in Q3 2023.
• Historically, Profit After Tax has averaged -$2.5 million across 5 years, with a median of -$3.7 million in 2021.
• The sharpest annual moves came in 2023 and 2025: Profit After Tax tumbled 146.69% in 2023, then soared 836.64% in 2025.
• A 5-year view of Profit After Tax shows it stood at -$4.3 million in 2021, then tumbled by 33.16% to -$5.7 million in 2022, then slumped by 142.26% to -$13.9 million in 2023, then jumped by 77.05% to -$3.2 million in 2024, then climbed by 29.84% to -$2.2 million in 2025.
• The last three Profit After Tax figures came in at -$2.2 million (Q4 2025), -$977000.0 (Q3 2025), and $3.9 million (Q2 2025), per Business Quant data.